Skip to Content
Merck
CN

59357-U

Discovery® Cyano (5 µm) HPLC Columns

L × I.D. 25 cm × 4.6 mm, HPLC Column

Synonym(s):

TM=["Discovery"] HPLC Chromatography

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52
L × i.d.:
25 cm × 4.6 mm
Particle size:
5 μm
Matrix active group:
cyano phase
Pore size:
180 Å
Matrix:
silica gel, high purity, spherical base material, fully porous particle

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Discovery® Cyano HPLC Column, 5 μm particle size, L × I.D. 25 cm × 4.6 mm

material

stainless steel column

agency

suitable for USP L10

product line

Discovery®

feature

endcapped

manufacturer/tradename

Discovery®

packaging

1 ea of

extent of labeling

4.5% Carbon loading

parameter

≤70 °C temp. range, 400 bar pressure (5801 psi)

technique(s)

HPLC: suitable, LC/MS: suitable

L × I.D.

25 cm × 4.6 mm

surface area

200 m2/g

surface coverage

3.5 μmol/m2

impurities

<10 ppm metals

matrix

silica gel, high purity, spherical base material, fully porous particle

matrix active group

cyano phase

particle size

5 μm

pore size

180 Å

operating pH range

2-8

application(s)

food and beverages

separation technique

hydrophilic interaction (HILIC), normal phase, reversed phase

Quality Level

100

Looking for similar products? Visit Product Comparison Guide

Related Categories

Features and Benefits

  • Low hydrophobicity for rapid elution of hydrophobic analytes
  • Excellent peak shape and retention of strongly basic analytes
  • Retention of polar analytes
  • Unique selectivity
  • Significantly less retention than C18 (typically requires lower % organic mobile phase)
  • Stable, low-bleed LC-MS separations
  • Compatible with highly aqueous organic phases

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
300749-06
300749-05
300749-04
300749-03
300749-02

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Thomas J Woltering et al.
Bioorganic & medicinal chemistry letters, 18(3), 1091-1095 (2007-12-22)
A series of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives was evaluated as non-competitive mGluR2/3 antagonists. Replacement of a cyano group by a five-membered heterocycle produced compounds inhibiting the binding of [(3)H]-LY354740 to rat mGluR2 with low nanomolar affinity and consistent functional effect at both
Fan Zhang et al.
European journal of medicinal chemistry, 46(7), 3149-3157 (2011-04-26)
A series of novel 2-amino-3-cyano-6-(1H-indol-3-yl)-4-phenylpyridine derivatives were synthesized and their cytotoxic activity against A549, H460, HT-29 and SMMC-7721 cell lines was evaluated in vitro. Among them, ten compounds (10, 11, 14, 16, 17, 26, 27, 29, 30 and 31) displayed
Graciela B Arhancet et al.
Journal of medicinal chemistry, 53(16), 5970-5978 (2010-08-03)
A new 1,4-dihydropyridine 5a, containing a cyano group at the C3 position, was recently reported to possess excellent mineralocorticoid receptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity. In the present study, we report the structure-activity relationships
T A Verdoorn et al.
European journal of pharmacology, 269(1), 43-49 (1994-09-15)
The diversity of neuronal glutamate receptors continues to increase with the discovery of multiple subunits and subunit families. The significance of this potential receptor heterogeneity is unknown because pharmacological tools that could clearly distinguish between different structural isoforms have not
K Umekawa et al.
Japanese journal of pharmacology, 84(1), 7-15 (2000-10-24)
We describe the pharmacological characteristics of SM-19712 (4-chloro-N-[[(4-cyano-3-methyl-1-phenyl-1H-pyrazol-5-yl)amino]carbonyl] benzenesulfonamide, monosodium salt). SM-19712 inhibited endothelin converting enzyme (ECE) solubilized from rat lung microsomes with an IC50 value of 42 nM and, at 10 - 100 microM, had no effect on other
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service